Paul Nouri, CFP
Contributor since: 2011
Company: Noble equity fund, lp
Latest Articles
Investors Are Left To Speculate On The Reasons For Rite Aid's Decision To Enter Into A Merger With A Binary Outcome
Investors Should Stop Kicking The Tires On Cooper
Amazon's Recent 'Entry' Into Healthcare Is Naive
SA Interview: Healthcare Investing With Paul Nouri, CFP
Shares Of The Cheesecake Factory Offer Relative Value In An Expensive Market
Expectations Might Be Overly Optimistic For OraSure As It Approaches The Billion Dollar Club
The Time Is Right For Brave Investors To Start Accumulating Rite Aid
Favorable Risk/Reward Profile Makes Trinity Biotech A Compelling Investment
Cogentix Represents A Growth Story In A Compelling Niche
CombiMatrix's Focus On Niche Diagnostic Markets Should Serve Shareholders Well
Abbott's Acquisition Of Alere May Lead To Value Destruction For Abbott Shareholders
Noble Equity Capital Management Issues Letter To Venaxis Shareholders
LeapFrog: Requiem For A Value Trap
Multibillion-Dollar Companies Continue To Marginalize Their Employees 6 Years Into The Recovery
Market Collapse A Lone Aberration Or A Warning Signal?
Recent IPO Medical Transcription Billing Looks Like A Value Play With Growth Opportunities
Return To Growth Could Send Diadexus Shares Higher
Lumenis: Shares In This Medical Device Maker Are Poised For Gains
Relative Value In Shares Of IT Solutions Provider Creates Opportunity
Could Medtronic Have Better Spent $43 Billion?
Valeant And Allergan Are Not A Match Made In Heaven
Life Is About Incentives, And The Fed Is Offering Up The Wrong Ones
Deep Value In This Diagnostic Company Might Attract Activists
Pharma Rollups In Midst Of A Bubble That Might Be About To Burst
The Time Is Right For Investors To Buy PetSmart
2013 Small And Micro Cap Picks Reviewed
LipoScience Has Become Too Cheap To Ignore
Congress & Administration Acting Like A Divorcing Couple In Negotiation
BlackBerry Is Probably Worth More Than The Consensus Estimates
One Test Could Add Significant Value At Chembio
Trinity Biotech: One Of The Most Inexpensive Names In Med-Tech With Catalysts
MGC Diagnostics Overhaul Should Reward Investors Over Next 12 Months